Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.8% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) specializes in automated insulin delivery systems for diabetes management, with a focus on technological advancements and global market expansion.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.8% on Jun 12, 2026 15:16

• Tandem Diabetes Care (TNDM) saw a notable increase in its stock price today driven by several positive factors:
• Encouraging results from studies on the company's fully closed loop automated insulin delivery system for Type 2 diabetes that eliminates carb-counting and insulin bolusing, leading to enhanced investor confidence.
• Obtaining CE Mark approval in Europe for expanded diabetes management indications, including pregnancy in Type 1 diabetes and adults with Type 2 diabetes, creating new market possibilities and strengthening Tandem's role in integrated diabetes care.
• Anticipation surrounding product innovations like the upcoming Mobi Tubeless launch and advancements in global expansion, promoting optimism about Tandem's future growth.
• Analysts' decision to maintain a Hold rating on Tandem Diabetes Care suggests a reserved outlook, potentially influenced by competitive market conditions despite positive company updates.
• Tandem's progress in technology, regulatory clearances, and market expansion strategies has spurred bullish activity in the stock price, indicating growing investor interest in the company's prospects within the diabetes management industry.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Why Insulet thinks its fully closed loop system will stand apart from rivals

Insulet is developing a "fully closed loop" automated insulin delivery system for Type 2 diabetes that distinguishes itself from competitors by requiring no carb-counting, insulin bolusing, or initial programming by physicians. The system, which automated dose titration and has no bolus button, showed promising results in its Evolution 3 study, improving participants' time in range and reducing total daily insulin without weight gain. Insulet also shared findings for its Omnipod 6 algorithm, designed for both Type 1 and Type 2 diabetes, which offers a lower glucose target and improved connectivity, with an FDA submission planned for this year and a launch next year.

https://www.medtechdive.com/news/why-insulet-thinks-its-fully-closed-loop-system-will-stand-apart-from-rival/822637/

BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $25

BofA Securities has reiterated its Hold rating on Tandem Diabetes Care (TNDM.US) and maintained its target price at $25. This indicates a neutral outlook on the company's stock from BofA Securities.

https://www.moomoo.com/news/post/71259331/bofa-securities-maintains-tandem-diabetes-care-tndmus-with-hold-rating

Should Tandem’s Expanded EU Diabetes Indications and ESOP Shelf Filing Require Action From Tandem Diabetes Care (TNDM) Investors?

Tandem Diabetes Care recently filed a US$47.40 million shelf registration for employee stock ownership and secured CE mark approval in Europe to expand the use of its automated insulin delivery systems for pregnancy in type 1 diabetes and adults with type 2 diabetes. This broader European certification could reinforce Tandem's role in integrated diabetes management and support its international growth, though competitive pressures remain a key risk. The article examines how these developments might influence Tandem's investment narrative, which forecasts $1.4 billion revenue and $63.4 million earnings by 2029.

https://simplywall.st/stocks/us/healthcare/nasdaq-tndm/tandem-diabetes-care/news/should-tandems-expanded-eu-diabetes-indications-and-esop-she

TNDM: Momentum builds with pharmacy transition, Mobi Tubeless launch, and international expansion

Tandem Diabetes Care (TNDM) is seeing strong momentum driven by product innovation, including the CE Mark for pregnancy indication and the upcoming Mobi Tubeless launch. The company is also progressing with its pharmacy channel transition to reduce costs and boost growth, alongside plans for international expansion and new technology initiatives to strengthen its market position. This positive outlook was highlighted at the Goldman Sachs 47th Annual Global Healthcare Conference.

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3521078:0-tndm-momentum-builds-with-pharmacy-transition-mobi-tubeless-launch-and-international-expansion/

Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

Tandem Diabetes Care has received CE Mark approval for its t:slim X2 and Tandem Mobi automated insulin delivery systems for expanded indications in Europe. These systems, utilizing Control-IQ+ AID technology, are now approved for use by individuals with type 1 diabetes during pregnancy and adults with type 2 diabetes. This expansion aims to broaden access to their AID technology and improve lives across the diabetes community, backed by clinical trial data published in JAMA and the New England Journal of Medicine.

https://www.biospace.com/press-releases/tandem-diabetes-care-automated-insulin-delivery-systems-receive-ce-mark-for-type-2-diabetes-and-type-1-diabetes-during-pregnancy

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 17.4% Today

Tandem Diabetes Care, Inc. Price History

04.05.2026 - TNDM Stock was up 8.9%

• Tandem Diabetes Care (TNDM) experienced a bullish movement today, likely driven by positive investor sentiment and growth prospects indicated by recent strategic business model transitions and international expansion efforts.
• The news of key executives, including the CEO and other officers, receiving significant RSU grants under the 2023 Long-Term Incentive Plan could have also contributed to the bullish momentum, signaling confidence in the company's future performance and aligning leadership interests with shareholder value.
• The reaffirmed 2026 guidance and strong solvency profile further reinforced investor confidence in Tandem's long-term prospects, despite near-term profitability challenges.
• Overall, the combination of growth initiatives, executive incentives, and financial stability likely fueled the bullish movement in TNDM stock today.

04.05.2026 - TNDM Stock was up 8.0%

• The positive sentiment surrounding Tandem Diabetes Care's (TNDM) leadership team receiving significant Restricted Stock Units (RSUs) under the 2023 Long-Term Incentive Plan could have contributed to the bullish movement in the stock market today. This act of granting equity awards may indicate confidence in the company's future performance.
• Granting RSUs to key executives, including the CEO, EVP, and CFO, helps align their interests with long-term shareholder value. This alignment might enhance investor confidence in TNDM's strategic direction and growth opportunities.
• Despite recent share price fluctuations and concerns over TNDM's valuation, the disclosure of equity awards to top management could potentially reassure investors about the company's dedication to driving sustainable growth and profitability, likely influencing the positive market movement.

01.05.2026 - TNDM Stock was down 6.5%

• TNDM stock saw a decrease today, possibly due to Citigroup maintaining a Neutral rating on the company but revising the price target downward from $22.00 to $17.00. This adjustment, influenced by market changes and competition, may have unsettled investors.
• GuruFocus suggested that TNDM is undervalued by 43.8% based on its GF Value™ and added a "Possible Value Trap" designation, along with insider selling. These factors might have contributed to the negative sentiment towards the stock.
• Despite the undervaluation, investors are advised to be cautious, which could have prompted some to sell their shares, further impacting the decline in TNDM stock today.

29.04.2026 - TNDM Stock was up 18.4%

• Maintaining a Neutral rating but lowering the price target could have initially caused some uncertainty, but the undervaluation by 43.8% may have sparked investor interest.
• The approval of an expanded long-term incentive plan and progress on new insulin pump launches indicate the company's commitment to long-term growth, potentially boosting investor confidence.
• The equity compensation activities of key figures like Chair Emeritus Dick Allen and Director Sandra Beaver, receiving RSUs and aligning their interests with shareholders, could have contributed to a positive outlook for the company.
• Overall, the combination of strategic growth initiatives, undervaluation, and alignment of interests through equity compensation may have driven the strong bullish movement in TNDM's stock today.

05.05.2026 - TNDM Stock was up 5.3%

• A recent insider trading activity involving the Chief Strategy Officer gifting shares to a family trust may have indicated confidence in the company's future outlook, contributing to favorable market sentiment.
• Tandem Diabetes Care's strategic shift in business model, efforts towards international expansion, and upcoming product launches are viewed as significant drivers for future revenue growth, appealing to investors.
• The recent allocation of Restricted Stock Units to the Chief Operating Officer may have also bolstered confidence in the leadership team's capabilities to propel the company's growth, further enhancing investor confidence.
• Despite concerns outlined in the valuation analysis, including competition and execution challenges, the overall positive developments and strategic initiatives by Tandem Diabetes Care appear to have outweighed these risks for investors, leading to the bullish market movement.

10.05.2026 - TNDM Stock was down 8.1%

• Notwithstanding Tandem Diabetes Care's recent milestones like obtaining CE mark approval in Europe for extended indications and introducing innovative products such as the Mobi Tubeless, the stock experienced a bearish trajectory today.
• The market's negative response may be attributed to concerns regarding competitive pressures and potential risks linked to global expansion.
• Some investors appear to be adopting a cautious stance on TNDM's capacity to achieve its ambitious revenue and earnings projections by 2029.
• Despite positive updates about the company, the prevailing sentiment towards Tandem Diabetes Care's stock appears to have been influenced by wider market conditions or particular investor perspectives, contributing to the downward movement in stock value.

12.05.2026 - TNDM Stock was up 5.8%

• Tandem Diabetes Care (TNDM) saw a notable increase in its stock price today driven by several positive factors:
• Encouraging results from studies on the company's fully closed loop automated insulin delivery system for Type 2 diabetes that eliminates carb-counting and insulin bolusing, leading to enhanced investor confidence.
• Obtaining CE Mark approval in Europe for expanded diabetes management indications, including pregnancy in Type 1 diabetes and adults with Type 2 diabetes, creating new market possibilities and strengthening Tandem's role in integrated diabetes care.
• Anticipation surrounding product innovations like the upcoming Mobi Tubeless launch and advancements in global expansion, promoting optimism about Tandem's future growth.
• Analysts' decision to maintain a Hold rating on Tandem Diabetes Care suggests a reserved outlook, potentially influenced by competitive market conditions despite positive company updates.
• Tandem's progress in technology, regulatory clearances, and market expansion strategies has spurred bullish activity in the stock price, indicating growing investor interest in the company's prospects within the diabetes management industry.

11.05.2026 - TNDM Stock was down 7.1%

• The company achieved CE Mark approval for expanded indications in Europe and made progress with product innovation. However, its stock trended bearishly.
• BofA Securities maintained a Hold rating and set a target price of $25, potentially impacting the lack of bullish momentum.
• Despite Tandem Diabetes Care's focus on international growth and new technological advancements, investors may be wary of competitive pressures within the diabetes management sector.
• The stock's recent positive performance and various news releases might have triggered profit-taking actions, influencing market response.

27.04.2026 - TNDM Stock was down 5.0%

• Shareholders' approval of an expanded long-term incentive plan and recent equity compensation activities involving key individuals at Tandem Diabetes Care could have raised concerns among investors regarding the company's long-term growth outlook and talent retention.
• The company's issuance of stock-based compensation and the granting of restricted stock units (RSUs) to directors may have sparked uncertainties about TNDM's financial stability and strategic path, leading to a lack of confidence in its future performance.
• Despite advancements in new insulin pump releases and optimistic revenue and earnings growth forecasts by 2029, the intensifying competition and possible margin pressures mentioned in recent updates might have contributed to TNDM's bearish market activity.
• The emphasis on aligning management and shareholder objectives for prolonged growth, while crucial, may have also highlighted existing hurdles and uncertainties within the company, further influencing investor sentiment and prompting the downward movement in TNDM's stock price.

08.05.2026 - TNDM Stock was down 5.4%

• The bearish movement in TNDM stock could be attributed to a reaction by investors to recent CE mark approvals in the EU for expanded indications of its insulin pumps.
• Despite the news of expanded clearances for Tandem's insulin pumps, the market may have already priced in these developments, leading to profit-taking by traders.
• The initial market response to the expanded indications might have subsided as investors reevaluated the potential impact on Tandem's revenue and market share in the highly competitive diabetes management sector.

02.05.2026 - TNDM Stock was down 5.4%

• An upgrade of Tandem Diabetes Care to "Overweight" with an increased price target to $27 did not prevent the bearish movement, indicating other market factors at play.
• Historical challenges, such as a significant decline in stock price over the past year and low return on equity, likely contributed to the bearish trend.
• The filing of a shelf registration for an ESOP-related offering and changes in director removal rules may have raised concerns among investors.
• Despite the recent surge in stock price and positive sales data, the overall market sentiment towards Tandem Diabetes Care remains cautious, emphasizing the need for a thorough evaluation of the company's long-term prospects.

09.05.2026 - TNDM Stock was down 5.1%

• Despite recent progress in product advancements and market expansion, a bearish trend in TNDM stock today may be due to profit-taking by investors following a period of strong performance.
• The market's negative reaction could stem from concerns regarding TNDM's ability to sustain growth amidst rising competition in the diabetes management industry.
• Some investors may have anticipated more substantial announcements from Tandem Diabetes Care, leading to a minor letdown and subsequent selling pressure on the stock.